Atea Pharmaceuticals: Best-In-Class HCV Cure With Pivotal Readouts In 2026 (NASDAQ:AVIR)

Atea Pharmaceuticals ( AVIR ) is developing antiviral treatments for hepatitis C (HCV) and hepatitis E (HEV) viruses. Their lead candidate is bemnifosbuvir/ruzasvir ((BEM/RZR)) being developed for HCV cure, currently being evaluated in two parallel phase 3 trials, one in North America andhttps://biotechpharmainvestor.substack.comBackground: Physician involved in clinical research. Investment style: Clinical-stage biotech stocks, long only, both long-term ideas and event-driven trading. My academic/medical b ...